曲氟尿苷替匹嘧啶联合贝伐珠单抗一线治疗不适合强化治疗的转移性结直肠癌:随机TASCO1研究
TASCO1研究是一项开放标签、非比较的II期研究,纳入153例不适合联合细胞毒化疗的未经治疗的不可切除转移性结直肠癌患者,随机1:1接受曲氟尿苷替匹嘧啶联合贝伐珠单抗(TT-B,N=77)或卡培他滨联合贝伐珠单抗(C-B,N=76)。主要终点无进展生存期(PFS)在TT-B组为9.2个月,C-B组为7.8个月;总生存期(OS)分别为18个月和16.2个月。两组生活质量无临床相关变化,安全性可接受。
要点
- TT-B组中位PFS为9.2个月,C-B组为7.8个月。
- TT-B组中位OS为18个月,C-B组为16.2个月。
- TT-B组≥3级中性粒细胞减少发生率47%,C-B组为5%。
核心结论
- 在未经治疗且不适合强化治疗的不可切除mCRC患者中,TT-B显示出有前景的临床活性,安全性可接受,生活质量无临床相关变化。
研究设计与样本
- 开放标签、非比较的II期随机研究,2016年4月29日至2017年3月29日纳入153例患者,随机1:1分配至TT-B组(N=77)或C-B组(N=76)。
主要发现
- TT-B组中位PFS为9.2个月(范围7.6-11.6),C-B组为7.8个月(范围5.5-10.1)。
- TT-B组中位OS为18个月(范围15.2至NA),C-B组为16.2个月(范围12.5至NA)。
- TT-B组中位治疗持续时间7.8个月(范围6.0-9.7),C-B组为6.2个月(范围4.1-9.1)。
- 生活质量问卷(QLQ-C30和QLQ-CR29)显示两种治疗随时间均无相关变化。
关键数值与推荐
- TT-B组≥3级中性粒细胞减少发生率为47%,C-B组为5%。
- C-B组≥3级手足综合征发生率为12%,TT-B组为0%。
- C-B组≥3级腹泻发生率为8%,TT-B组为1%。
临床怎么用
- 对于不适合联合细胞毒化疗的未经治疗mCRC患者,TT-B可作为一线治疗选择之一,但需注意中性粒细胞减少。
局限性
- 本研究为开放标签、非比较的II期研究,样本量有限,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies. PATIENTS AND METHODS: From 29 April 2016 to 29 March 2017, 153 patients were randomly assigned (1:1) to either TT-B (N = 77) or C-B (N = 76). The primary end point was progression-free survival (PFS). The primary PFS analysis was performed after 100 events (radiological progression or death) were observed. Secondary end points included overall survival (OS), quality of life (QoL; QLQ-C30 and QLQ-CR29 questionnaires), and safety. RESULTS: Median (range) duration of treatment was 7.8 (6.0-9.7) months and 6.2 (4.1-9.1) months in the TT-B and C-B groups, respectively. Median (range) PFS was 9.2 (7.6-11.6) and 7.8 (5.5-10.1) months, respectively. Median (range) OS was 18 (15.2 to NA) and 16.2 (12.5 to NA) months, respectively. QoL questionnaires showed no relevant changes over time for either treatment. Therapies were well tolerated. Patients receiving TT-B had more grade ≥3 neutropenia (47% versus 5% with C-B). Patients receiving C-B had more grade ≥3 hand-foot syndrome (12% versus 0% with TT-B) and grade ≥3 diarrhea (8% versus 1% with TT-B), consistent with the known safety profiles of these agents. CONCLUSION: TT-B treatment showed promising clinical activity in untreated patients with unresectable mCRC ineligible for intensive therapy, with an acceptable safety profile and no clinically relevant changes in QoL. CLINICAL TRIAL INFORMATION: NCT02743221 (ClinicalTrials.gov).
引用
- Van Cutsem E, Danielewicz I, Saunders MP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol. 2020. PMID: 32497736. doi:10.1016/j.annonc.2020.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。